- People starting an SGLT2 inhibitor sooner after severe kidney injury had fewer adverse kidney outcomes in an observational study.
- The analysis involved adults with type 2 diabetes who had needed dialysis but had subsequently stopped it.
- The findings do not justify starting or restarting medication without a clinician reviewing recovery and safety.
Leaving hospital after a severe kidney injury does not always settle the question of when to begin protective treatment.
Kidney function, blood pressure and fluid balance may still be changing, leaving clinicians to weigh the benefits of treatment against the risks of starting too soon.
Research from National Taiwan University Hospital examined that decision for SGLT2 inhibitors, medicines used in type 2 diabetes that also have established roles in kidney and heart protection.
The study identified 4,406 adults who had required dialysis during an acute kidney injury, subsequently stopped dialysis and received their first SGLT2 prescription within 90 days of leaving hospital.
Researchers compared those starting within 30 days with those starting between 31 and 90 days.
Statistical matching produced two groups of 1,912 people for the main comparison.
Adverse kidney outcomes occurred in 3.9% of the earlier-treatment group and 6.2% of the later-treatment group.
After adjustment, earlier treatment was associated with a 38% lower hazard of the combined kidney outcome.
The detail behind that result matters.
The difference was mainly driven by fewer people reaching a very low kidney filtration rate.
There was no statistically significant difference in restarting dialysis, death or major cardiovascular events.
Recorded safety outcomes over six months were also similar between groups.
This was an analysis of medical records, not a randomised trial. People well enough to receive treatment earlier may have differed from those whose clinicians waited, despite the efforts to make the groups comparable.
The researchers therefore describe the findings as a reason for prospective trials, not proof of a universal 30-day deadline.
- Research suggests GLP-1 and SGLT2 diabetes medications may reduce dementia risk
- High blood pressure can trigger kidney alterations
There is also an important distinction between recovery after an illness and the illness itself.
UK kidney guidance advises temporarily pausing SGLT2 inhibitors during acute illness, particularly when someone cannot maintain food or fluid intake, with treatment reviewed once they recover.
For patients, the useful question at a discharge review is whether there is a clear plan for medicines that were stopped or are being considered.
This research suggests unnecessary delay may deserve attention. It does not mean someone should start a tablet while dehydrated or unwell, or change a kidney specialist’s plan based on a headline.
